Search Results
Your search for can matches 13758 pages
Showing 3851 - 3900Updates From Selected Clinical Trials in Breast Cancer
Each year, following the San Antonio Breast Cancer Symposium (SABCS), The ASCO Post asks Jame Abraham, MD, FACP, to offer his picks of the most important and most clinically relevant research presented at this meeting. The following are summaries of studies that caught Dr. Abraham’s attention from ...
PHOEBE Trial: Pyrotinib/Capecitabine vs Lapatinib/Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With Trastuzumab
In a prespecified interim analysis of the Chinese phase III PHOEBE trial reported in The Lancet Oncology, Xu et al found that the combination of the irreversible pan-HER inhibitor pyrotinib plus capecitabine significantly prolonged progression-free survival vs lapatinib plus capecitabine in...
The Impact of a Pandemic on Mentorship in Medicine
When advising the younger members of our medical community on career decisions, I always list “access to the best mentorship” as the most important priority. By the time we hit residency, we have all proven ourselves able to extract from a book or a journal the facts essential to the practice of...
New Report Reviews Methods for Reducing Waste, Improving Efficiency With Expensive Injectable Medications
Every year, significant amounts of drugs left over and unused from single-dose vials are discarded, but because of the way drugs are priced and paid for in the United States, the cost of the discarded amount cannot be recouped, according to a new congressionally mandated report from the National...
New Framework to Address Cancer Care Disparities in Medically Underserved Populations
A new article published in JCO Oncology Practice puts forth a framework to guide researchers, health-care leaders, advocates, community- and patient-focused service organizations, and policy leaders in their work to address and promote health equity in cancer care access and treatment outcomes.1...
ASCO Names Advance of the Year: Molecular Profiling Drives Progress in Gastrointestinal Cancers
Molecular profiling allows clinicians to identify the molecular and genetic signatures that help to deliver treatments that are highly specific to a tumor. This tool has made possible a number of advances in the past year that are improving care for patients with gastrointestinal cancers. In...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Kenya
The ASCO Post is pleased to continue this occasional special focus on the worldwide cancer burden. In this issue, we feature a close look at the cancer incidence and mortality rates in Kenya. The aim of this special feature is to highlight the global cancer burden for various countries of the...
I Let Science, Not Emotion, Dictate My Treatment
I had my first experience with cancer when I was just 3 or 4 years old and complained to my mother that my “tummy hurt.” I was diagnosed with Wilms tumor, the same cancer my 18-month-old brother died of before I was born. I remember being in the hospital for weeks at a time and being known by...
Crystal Denlinger, MD, FACP, Named Chief Scientific Officer for NCCN
The National Comprehensive Cancer Network© (NCCN) recently announced the appointment of Crystal S. Denlinger, MD, FACP, to the newly created role of Senior Vice President, Chief Scientific Officer. In this position, Dr. Denlinger will help to steer strategic direction for the nonprofit as well as...
When to Start a Conversation With Patients About Subsequent Primary Cancers
Among patients who survive a primary cancer, concern about recurrence, especially metastatic disease, is extremely common; however, information about future risk for subsequent primary cancers is seldom communicated to these patients, leading to missed opportunities to prevent or detect subsequent...
Ongoing Surveillance and Efforts to Reduce Smoking and Obesity Needed to Lower Cancer Survivors’ Risks of New Cancers
The risk of developing or dying of a new primary cancer, particularly those cancers associated with smoking and obesity, was greater among survivors of adult-onset cancers than the expected risk in the general population, according to an analysis of data from more than 1.5 million cancer...
Professor Gordon McVie, International Cancer Researcher and Patient Advocate, Dies at 76
An imposing painting of sailing ships graced the wall behind the desk in the office of Professor Gordon McVie, BSc (Hons), MBChB, MD, FRCP, FRCPEd, FRCPS (Glas), FMedSci, DSc. It was a gift from one of his patients with cancer, a long-term survivor who said the painting reminded her of him, walking ...
Conversations With the Pioneers of Oncology: Emil J Freireich, MD, FASCO
To hear an interview with Dr. Freireich by Daniel F. Hayes, MD, FASCO, of the University of Michigan Rogel Cancer Center and Past President of ASCO, visit the Journal of Clinical Oncology’s podcast, Cancer Stories, wherever you get your podcasts. In this episode, the Cancer Stories podcast reflects ...
COVID-19 and Cancer: A Toxic Combination
COVID-19 has caused 475,000 deaths in America, disproportionately among communities of color, poverty, immigrants, and older age. It has exposed a variety of inequities within our health-care system. However, the patients at greatest risk of death from COVID-19 are those with cancer. While 1.8% of...
Novel Approaches in Chronic Lymphocytic Leukemia
To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel therapeutic approaches in chronic lymphocytic leukemia (CLL). For full...
Expert Point of View: Rachna T. Shroff, MD, and Gentry King, MD
Invited study discussant Rachna T. Shroff, MD, Associate Professor of Medicine, University of Arizona, and Chief of GI Medical Oncology at the University of Arizona Cancer Center, said the study presented by Dr. Javle1 showed the FGFR2 inhibitor infigratinib to be active in FGFR2 fusion–positive...
B-Cell and T-Cell Non-Hodgkin Lymphomas
To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on the assessment and treatment of patients with B-cell and T-cell non-Hodgkin...
How the COVID-19 Pandemic Can Help Improve Cancer Research
The ripple effects of the coronavirus pandemic have been felt in every area of health care. In our medical specialty, oncology, clinical trials of new treatments were upended by COVID-19. In the early months of the pandemic, widespread interruptions in trial enrollment prevented some patients...
Updated Findings Bolster the Use of Checkpoint Inhibitors in Treatment of Liver Cancer
Although optimal regimens are still being determined, checkpoint inhibition has clearly established itself in the treatment of hepatocellular carcinoma, as judged by the number of abstracts on the topic at the 2021 Gastrointestinal Cancers Symposium. The ASCO Post brings readers short summaries of ...
Expert Point of View: Meredith Regan, ScD, and Sara Hurvitz, MD
In the San Antonio meeting’s closing session, “View From the Trenches: What Will You Do Monday Morning?” Meredith Regan, ScD, and Sara Hurvitz, MD, offered their thoughts on the use of RSClin in the clinic, as described at the San Antonio Breast Cancer Symposium by Joseph Sparano, MD.1 Dr. Regan...
Can Weight Loss During Treatment and Follow-up Affect Breast Cancer Outcomes?
Research published by Martel et al in JNCCN—Journal of the National Comprehensive Cancer Network examined body mass index (BMI) data for patients with HER2-positive early breast cancer—and found a 5% weight loss in patients over 2 years was associated with worse outcomes. Weight gain over the same...
NEOSTAR: Neoadjuvant Nivolumab or Nivolumab/Ipilimumab in Operable NSCLC
The randomized phase II NEOSTAR trial, which examined single-agent and combined neoadjuvant immune checkpoint inhibitor therapy in patients with stage I to III non–small cell lung cancer (NSCLC), found combination therapy produced a significant clinical benefit (as assessed by major pathologic...
New Recommendations Aim to Eliminate Racial Disparities in Multiple Myeloma Therapies and Trials
Recommendations designed to address the underrepresentation of Black patients in clinical trials for multiple myeloma were recently released. Details about the initiative, published by Gormley et al in Blood Cancer Discovery, form a road map for designing multiple myeloma clinical trials to...
Transplant May Improve Survival in Older Patients With High-Risk Myelodysplastic Syndrome
Stem cell transplants are not frequently offered to older patients with high-risk myelodysplastic syndromes (MDS). According to a study from the Blood and Marrow Transplant Clinical Trials Network (BMTCTN 1102), these patients may indeed achieve a survival benefit from stem cell transplant. As...
Belantamab Mafodotin-blmf Plus Pomalidomide and Dexamethasone Elicits Responses in Myeloma
Belantamab mafodotin-blmf combined with pomalidomide and dexamethasone led to a very good partial response (VGPR) or better in approximately three-quarters of patients with multiple myeloma that was double-class or triple-class refractory, according to Suzanne Trudel, MSc, MD, FRCPC, of Princess...
Expert Point of View: Ajay K. Nooka, MD, MPH, FACP
Ajay K. Nooka, MD, MPH, FACP, Associate Professor of Hematology and Medical Oncology at Emory University and Medical Director, Winship Research Informatics Shared Resource at Winship Cancer Institute, Atlanta, considered the presentations on bispecific T-cell–engaging antibodies in myeloma to be...
Subcutaneous Daratumumab Meets Primary Endpoint in APOLLO Trial in Myeloma
The first phase III study to evaluate the subcutaneous form of daratumumab has met its primary endpoint, investigators of the APOLLO trial reported at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.1 The triplet of daratumumab, pomalidomide, and low-dose dexamethasone ...
Treatment With LOXO-305 Results in Durable Efficacy in Heavily Pretreated Patients With CLL/SLL
Despite the marked efficacy of ibrutinib, acalabrutinib, and venetoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), treatment failure can occur through the development of resistance. In addition, patients in whom Bruton’s tyrosine kinase (BTK) inhibitors and BCL2...
Overcoming CD58 Loss May Be Promising Path to Overcoming Resistance to CAR T-Cell Therapies
Engineering chimeric antigen receptor (CAR) T cells to overcome CD58 loss may be a way to boost responses in patients with diffuse large B-cell lymphoma (DLBCL) who do not respond to treatment with axicabtagene ciloleucel and other CAR T-cell therapies, according to a study presented at the 2020...
Chemotherapy Plus Blinatumomab for Philadelphia Chromosome–Negative B-Cell ALL
Results from a phase II study presented by Nicholas J. Short, MD, and colleagues at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition showed that first-line treatment with a regimen of chemotherapy combined with the monoclonal antibody blinatumomab resulted in increased...
Expert Point of View: David Snyder, MD
David Snyder, MD, Acting Chair, City of Hope Department of Hematology & Hematopoietic Cell Transplantation, Duarte, California, who was not involved in the ASCEMBL study, commented on the promise of asciminib: “The hope is this drug would be able to overcome resistance to other tyrosine kinase...
Study Finds Asciminib Safer, More Effective Than Bosutinib in Chronic-Phase CML
Since the introduction of imatinib almost 18 years ago, similar next-generation tyrosine kinase inhibitors have been approved for chronic myeloid leukemia (CML), including dasatinib, nilotinib, bosutinib, and ponatinib. These drugs attack a similar target, making it more likely that resistance to...
ASH 2020 Meeting Highlights
The world of hematologic malignancies continues to move forward at a robust pace despite the challenges of the COVID era. Although some areas of clinical trials and basic research suffered short-term stoppages or delays due to the pandemic, the studies presented at the 2020 American Society of...
Comparison of Imaging Regimens for Stage I Seminoma After Orchiectomy
Men who have had treatment for early-stage testicular cancer may benefit from fewer monitoring scans, freeing them from some of the harmful radiation that comes from computerized tomography (CT) imaging, according to results from the phase III TRISST clinical trial presented by Joffe et al at the...
Joint ASCO/ACS CAN Letter: States Must Include Patients With Cancer on Their COVID-19 Vaccine Priority Lists
In the midst of growing concerns that patients with cancer have limited access to the COVID-19 vaccines, the Association for Clinical Oncology (ASCO) and American Cancer Society Cancer Action Network (ACS CAN), the advocacy affiliate of the American Cancer Society, issued a joint letter to every...
Prevalence of Cisplatin-Related Hearing Loss in Pediatric, Adolescent, and Young Adult Patients
Cisplatin is one of the most effective chemotherapy agents, used in just under half of pediatric cancer cases. Permanent hearing loss is a common side effect of this medication, but previous studies have been too small and too varied to accurately characterize this risk. In a new study published by ...
Updated Recommendations on the Treatment of Multiple Myeloma–Related Bone Disease From the Bone Working Group of the International Myeloma Working Group
In a policy review reported in The Lancet Oncology, Terpos et al presented updated recommendations from the Bone Working Group of the International Myeloma Working Group on the treatment of multiple myeloma–related bone disease. The recommendations cover: bisphosphonate use/dosing and management of ...
New Report Says Cancer and Its Therapies May Impair Survivors' Ability to Work
Although cancer survivors are living longer, cancer and its treatment can result in long-lasting or late-onset impairments that may affect their ability to work, according to a new report from the National Academies of Sciences, Engineering, and Medicine entitled Diagnosing and Treating Adult...
Fecal Microbiota Transplants May Help Patients With Advanced Melanoma Respond to Immunotherapy
For patients with melanoma who do not respond to treatment with immunotherapy, adjusting the composition of microorganisms in the intestines through the use of fecal transplants may aid in overcoming resistance to therapy. These findings were published by Davar et al in Science. In the study, some...
Genetic Mutations Linked to Worse B-Cell ALL Outcomes in Pediatric Hispanic and Latino Patients
A combination of genetic mutations may explain the higher incidence of and poorer outcomes from pediatric leukemia in Hispanic and Latino patients, according to a new study published by Raca et al in the journal Leukemia. Researchers said a novel therapeutic drug combination—as well as testing for...
FDA Approves Trilaciclib to Reduce Chemotherapy-Induced Bone Marrow Suppression in Adults Being Treated for SCLC
On February 12, the U.S. Food and Drug Administration (FDA) approved trilaciclib (Cosela) as the first therapy in its class to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage small cell lung cancer (SCLC)....
Implications of Delaying Surgery for Renal Cell Carcinoma During the COVID-19 Pandemic
During the peak of the COVID-19 pandemic, several elective surgeries for renal cell carcinoma were delayed, with an unknown impact on outcomes for patients. In a retrospective study, researchers from Rutgers Cancer Institute of New Jersey explored the impact of surgical delays for these patients...
ASCO Congratulates Joseph R. Biden, Jr, on Presidential Inauguration
“On the eve of his inauguration, the Association for Clinical Oncology (ASCO) congratulates Joseph R. Biden, Jr, the 46th President of the United States. “ASCO shares the President’s commitment to ensuring equitable high-quality cancer care for every American, and recently released a policy...
High-Risk Cutaneous Squamous Cell Carcinomas: The Present and Future
Cutaneous squamous cell carcinoma is the second most common type of skin cancer, with more than 1 million cases diagnosed in the United States annually.1 Historically, cutaneous squamous cell carcinoma is grouped together with basal cell carcinoma and collectively referred to as nonmelanoma skin...
Trading One Disease for Another: Patients With Chronic Graft-vs-Host Disease May Face Lifelong Complications
The field of allogeneic stem cell transplantation continues to improve survival for patients with previously incurable blood cancers. However, up to 50% of patients who undergo transplantation with donor cells will develop chronic graft-vs-host disease, a potentially deadly condition that can also...
Expert Point of View: Shoshana Rosenberg, ScD, MPH
Shoshana Rosenberg, ScD, MPH, Assistant Professor of Medicine at Dana-Farber Cancer Institute and Harvard Medical School, Boston, weighed in on the implications of these findings. “The study underscores the importance of addressing psychosocial health in survivorship. it targeted a particularly...
Meditation and Education Interventions May Improve Depressive Symptoms in Young Breast Cancer Survivors
A diagnosis of breast cancer and subsequent treatment may increase the risk of depression, especially among younger women with breast cancer. A new study showed that behavioral interventions—specifically mindfulness meditation and survivorship education classes—may reduce depressive symptoms, as...
Novel Insights Into Multiple Myeloma
“Knowledge has a beginning but no end.” —Geeta Iyengar To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are three abstracts selected from the meeting proceedings focusing on novel therapies for...
COVID Virus–Specific T Cells: Potential Treatment of Severe COVID-19 Infection Under Study
It may be possible to exploit T cells from healthy volunteers who have recovered from COVID-19 as a treatment for this viral infection. Researchers at the Center for Cell and Gene Therapy at Baylor College of Medicine have designed an off-the-shelf COVID virus–specific T-cell product (called...
Expert Point of View: Deepa Jagadeesh, MD, MPH
“Although some B-cell lymphomas are highly curable, this goal remains elusive for most T-cell lymphomas (TCL). Refractory and relapsed disease post induction therapy remains a major challenge in management,” said Deepa Jagadeesh, MD, MPH, Assistant Professor, Cleveland Clinic Lerner College of...
